ea0041gp67 | Clinical Case Reports | ECE2016
, Sendur Suleyman Nahit
, Demirkazik Ahmet
, Dagdelen Selcuk
, Erbas Tomris
Nivolumab is the first programmed death 1 (PD-1) immune checkpoint inhibitor. It is approved for use in advanced melanoma and squamous non small cell lung cancer (NSCLC). PD-1 immune checkpoint inhibitors can cause autoimmune disease of endocrine glands, including the thyroid. Here, we present a case of thyroiditis after nivolumab therapy.A 61 year-old female patient with NSCLC was consulted to endocrinology department for abnormal thyroid function test ...